california department of education
california department of education with http://www.mdnewscast.net

california department of education

Medical Newscast

News for 01-Apr-25

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Source: MedicineNet High Blood Pressure General
More Research Cites Salt's Potential Health Risks

Source: MedicineNet High Blood Pressure General
High Blood Pressure Rates Have Doubled Worldwide Since 1975

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet High Blood Pressure General
Even Small Rise in Blood Pressure Can Harm Black Patients

Source: MedicineNet Diabetes General
Can Protein, Probiotics Help With Blood Sugar Control?

Source: MedicineNet High Blood Pressure General
Omega-3s a Recipe for Healthy Blood Pressure in Young Adults

Source: MedicineNet High Blood Pressure General
Yoga Called Good Medicine for High Blood Pressure

Search the Web
california department of education
national education
education authority
teacher education
character education
education programs
education standards
county office of education
department education
education foundation

The Best california department of education website

All the california department of education information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best california department of education site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
california department of education.

california department of education

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

If you have spent countless hours searching for california department of education information, relax, put up your feet because you have landed at web site which is a california department of education gold mine. We are passionate about california department of education and have become real experts on the subject and just know you will be delighted with the wealth of information you will find on our site.

We have spent many hours of research into california department of education and conducted our own search procedures into the subject to find the worthwhile web sites that carry solid california department of education information. Below are links to the very best sites we found and encourage you to visit them, we promise you will not be disappointed.

california department of education

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

The internet is growing at an enormous rate these days and all the information on california department of education that's out there can take a long time to sift through. It took a long time, and a lot of hard work, for us to go through every information source about california department of education and pick out just a couple of the very best sites for you to visit.

We trust that you'll find our judgement sound. Like you we're very interested in california department of education, which is why we wrote this page about it. Right now I guess you should click on one of the links or zoom straight to the california department of education site that probably popped up when you entered this page. Thanks for visiting here.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Take It Right | Medical Meetings | MD News | MD Meetings | MD Newscast

fantasy-sports-directory   Medical Meetings   Fantasy Football Information